Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating reiterated by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $75.00 target price on the biotechnology company's stock. HC Wainwright's price target suggests a potential downside of 35.93% from the company's current price. HC Wainwright also issued estimates for Sarepta Therapeutics' Q1 2025 earnings at $2.45 EPS and Q4 2025 earnings at $2.85 EPS.

Other research analysts also recently issued reports about the stock. Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. UBS Group boosted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Raymond James restated an "outperform" rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Robert W. Baird reduced their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Finally, Needham & Company LLC restated a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $178.71.

Sarepta Therapeutics Trading Down 1.9 %

NASDAQ SRPT traded down $2.27 on Wednesday, hitting $117.06. The company's stock had a trading volume of 829,494 shares, compared to its average volume of 802,509. The firm has a market cap of $11.18 billion, a P/E ratio of 93.65 and a beta of 0.77. Sarepta Therapeutics has a 52-week low of $102.15 and a 52-week high of $173.25. The company's 50-day simple moving average is $121.75 and its 200 day simple moving average is $130.06. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. raised its stake in Sarepta Therapeutics by 14.1% during the 2nd quarter. American Century Companies Inc. now owns 7,184 shares of the biotechnology company's stock valued at $1,135,000 after buying an additional 889 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Sarepta Therapeutics by 19.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 4,312 shares of the biotechnology company's stock worth $681,000 after buying an additional 708 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 69.1% in the second quarter. Envestnet Asset Management Inc. now owns 68,679 shares of the biotechnology company's stock worth $10,851,000 after acquiring an additional 28,073 shares during the period. WINTON GROUP Ltd purchased a new stake in Sarepta Therapeutics during the second quarter valued at $425,000. Finally, Dimensional Fund Advisors LP increased its position in Sarepta Therapeutics by 13.9% during the second quarter. Dimensional Fund Advisors LP now owns 255,396 shares of the biotechnology company's stock valued at $40,353,000 after acquiring an additional 31,105 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.